<i>Lactobacillus plantarum </i>ZUST49 and bacterial agent, and use thereof

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Sulforaphane, derived from glucoraphanin, is unstable and difficult to maintain in traditional health products, requiring cold chain storage and having a short shelf life, while existing probiotic forms face challenges in survival and protection during digestion.

Innovation Solution

A Lactobacillus plantarum ZUST49 strain capable of converting glucoraphanin into sulforaphane in the intestinal environment, formulated into an enteric probiotic preparation with glucoraphanin, ensuring stability and efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If sulforaphane is extracted and encapsulated for health products, then it can be used in medicine and health products, but it requires cold chain storage and has a short shelf life due to poor stability

Engineering Contradiction:

Improvestability of sulforaphaneVSAvoidshelf life

Core Design Contradiction:

ReliabilityVSDuration of action of stationary object

Solution Approach 1:

The patent uses glucoraphanin as an intermediary substance that is stable during storage and only converts to sulforaphane when needed (in the intestinal environment). This mediator approach allows the product to maintain stability during storage while still delivering the active compound sulforaphane when consumed, resolving the contradiction between stability and effectiveness.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Ease of operation

If liquid preparation is used for probiotics, then it is easy to operate, but probiotics cannot survive for a long time

Engineering Contradiction:

Improveease of useVSAvoidsurvival time of probiotics

Core Design Contradiction:

Ease of operationVSDuration of action of stationary object

Solution Approach 1:

The patent employs enteric capsule coating technology to protect probiotics from the harsh gastric environment. The capsule shell acts as a protective barrier that allows the probiotics to survive stomach acid and release them in the intestinal environment, thereby extending their survival time while maintaining ease of administration as an oral capsule.

Inventive Principle:

Principle #30Flexible shells and thin films

3Stability of the object's composition

If tablets are used for probiotics, then they are stable during processing, but the number of viable probiotics is relatively low due to high temperature drying and moisture susceptibility

Engineering Contradiction:

Improvestability during processingVSAvoidnumber of viable probiotics

Core Design Contradiction:

Stability of the object's compositionVSQuantity of substance

Solution Approach 1:

The patent changes the processing parameters from high-temperature drying (tablets) to low-temperature freeze-drying or spray drying. This parameter change allows for better preservation of probiotic viability while still achieving a stable, dry powder form that can be processed and stored effectively. The enteric capsule formulation further protects the probiotics during storage.

Inventive Principle:

Principle #35Parameter changes

4Speed

If traditional gelatin capsules are used, then they dissolve faster than tablets, but they disintegrate in the stomach making it difficult for probiotics to be protected

Engineering Contradiction:

Improvedissolution speedVSAvoidgastric acid damage

Core Design Contradiction:

SpeedVSObject-affected harmful factors

Solution Approach 1:

The patent applies enteric coating technology that creates different properties at different locations: the capsule shell is designed to resist dissolution in the acidic stomach environment (protective quality) while dissolving in the more neutral intestinal environment (release quality). This local quality differentiation allows the probiotics to be protected during gastric passage and then released where they can survive and function.

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The Lactobacillus plantarum ZUST49 effectively converts glucoraphanin to sulforaphane in the intestines, enhancing stability and probiotic activity, and the enteric formulation protects the bacteria during digestion.

Implementation Method 1

Studies have shown that sulforaphane is obtained from the enzymolysis of glucoraphanin (4-methylsulfinylbutenyl glucosinolate) by myrosinase

Methodology Applied

Scientific EffectEnzymatic hydrolysis: Hydrolysis

Implementation Method 2

Lactobacillus plantarum ZUST49 strain capable of converting glucoraphanin into sulforaphane

Methodology Applied

Scientific EffectBiocatalysis: Catalysis

Data Source

PatentUS12599640B2<i>Lactobacillus plantarum </i>ZUST49 and bacterial agent, and use thereof

Publication Date: 2026.04.14 ZHEJIANG UNIV OF SCI & TECH

AI summary

The present disclosure discloses a Lactobacillus plantarum ZUST49 and a bacterial agent, and use thereof, and belongs to the technical field of microorganisms. An aspect of the present disclosure provides a Lactobacillus plantarum ZUST49 and a bacterial agent containing the Lactobacillus plantarum ZUST49, and another aspect provides use of the Lactobacillus plantarum ZUST49 and the bacterial agent containing the Lactobacillus plantarum ZUST49. The Lactobacillus plantarum ZUST49 of the present disclosure may convert glucoraphanin into sulforaphane, especially in a human or animal intestinal environment. After an enteric probiotic preparation prepared from the strain of the present disclosure is orally taken, the Lactobacillus plantarum ZUST49 may efficiently convert the glucoraphanin into the sulforaphane in an intestinal tract, which not only solves a problem that stability of the sulforaphane cannot be improved in the prior art, but also effectively exerts a probiotic effect.